2023. Overall survival and role of programmed death ligand 1 expression in patients with metastatic non-small-cell lung cancer and immunotherapy: an observational study from central Switzerland. Swiss Medical Weekly. 153, 1 (Jan. 2023), 40039. DOI:https://doi.org/10.57187/smw.2023.40039.